SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

79.55 1.66

Résumé

Variation du prix de l'action

24h

Actuel

Min

77.8

Max

79.95

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

33.602

67.147

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.85% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

79M

4.1B

Ouverture précédente

77.89

Clôture précédente

79.55

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2026, 23:08 UTC

Résultats

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 23:07 UTC

Résultats

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 22:20 UTC

Résultats

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 avr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 avr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 avr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 avr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 avr. 2026, 23:22 UTC

Résultats

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 avr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 avr. 2026, 22:52 UTC

Résultats

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 22:33 UTC

Résultats

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 avr. 2026, 22:32 UTC

Résultats

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 avr. 2026, 22:32 UTC

Résultats

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 avr. 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 avr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 avr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 avr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 avr. 2026, 22:05 UTC

Résultats

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 avr. 2026, 21:57 UTC

Résultats

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 avr. 2026, 21:56 UTC

Résultats

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 avr. 2026, 21:56 UTC

Résultats

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 avr. 2026, 21:55 UTC

Résultats

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 avr. 2026, 21:54 UTC

Résultats

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 avr. 2026, 21:54 UTC

Résultats

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 avr. 2026, 21:53 UTC

Résultats

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 avr. 2026, 21:49 UTC

Résultats

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 avr. 2026, 21:49 UTC

Résultats

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

8.85% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  8.85%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat